

C19orf28 antibody - middle region

Rabbit Polyclonal Antibody Catalog # AI12528

Product Information

Application WB, IHC Primary Accession Q6NUT3

Other Accession NM 001042680, NP 001036145

Reactivity Human
Predicted Human
Host Rabbit
Clonality Polyclonal
Calculated MW 52075

Additional Information

Gene ID 126321

Alias Symbol MGC20700, PP3501, C19orf28

Other Names Major facilitator superfamily domain-containing protein 12, MFSD12,

C19orf28

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium

azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-C19orf28 antibody concentration is 1

mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at

20°C. Avoid repeat freeze-thaw cycles.

Precautions C19orf28 antibody - middle region is for research use only and not for use in

diagnostic or therapeutic procedures.

Protein Information

Name MFSD12 {ECO:0000303 | PubMed:29025994,

ECO:0000312 | HGNC:HGNC:28299}

Function Transporter that mediates the import of cysteine into melanosomes, thereby

regulating skin pigmentation (PubMed:33208952, PubMed:37751742). In melanosomes, cysteine import is required both for normal levels of cystine, the oxidized dimer of cysteine, and provide cysteine for the production of the cysteinyldopas used in pheomelanin synthesis, thereby regulating skin pigmentation (PubMed:33208952). Also catalyzes import of cysteine into lysosomes in non-pigmented cells, regulating lysosomal cystine and cysteine storage, which is essnetial for redox homeostasis (PubMed:33208952,


PubMed:37751742).

Cellular Location Melanosome membrane; Multi-pass membrane protein. Lysosome


membrane; Multi-pass membrane protein

Tissue Location Widely expressed, with high expression in primary melanocytes.

Images



Human kidney



WB Suggested Anti-C19orf28 Antibody Titration: 0.2-1 μ g/ml Positive Control: HepG2 cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.